Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
28 janv. 2020 08h02 HE
|
Seelos Therapeutics, Inc.
Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos...
Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
22 janv. 2020 07h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)
10 janv. 2020 07h31 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)
06 janv. 2020 08h02 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
13 déc. 2019 08h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
04 déc. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
27 nov. 2019 11h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
20 nov. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)
18 nov. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...